Zenas BioPharma, Inc. (ZBIO)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
27.88 USD
-0.86
(-2.992%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 27.78 -0.10 (-0.100%) ⇩ (July 13, 2026, 7:31 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:20 a.m. EDT
Zenas BioPharma presents a classic high-risk biotech dilemma where the business fundamentals are currently non-existent due to losses and no earnings, yet the balance sheet remains surprisingly robust with a current ratio of nearly 12x. This creates a disconnect: the company is financially safe from bankruptcy, but the stock offers zero income and negative growth metrics. The recent price action shows a recovery from the yearly low, yet the statistical forecasting models are completely broken, offering zero confidence in predicting the next move. While insiders buying shares provides a glimmer of confidence, the options market is screaming for a binary outcome—either a miraculous clinical success driving the price to 45 or a disaster sending it lower. Without a catalyst to convert this speculative interest into a trend, the investment case remains neutral; it is a speculative vehicle for asymmetric bets, not a fundamental investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.099001 |
| AutoTheta | 0.104120 |
| AutoETS | 0.104307 |
| AutoARIMA | 0.104309 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 7.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 79.454 |
| Market Cap | 1,760,158,464 |
| Forward P/E | -12.31 |
| Website | https://zenasbio.com |
As of July 11, 2026, 3:20 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. There is heavy open interest in deep out-of-the-money calls (strikes like 35 and 45) suggesting a hope for a massive biotech-style spike, while deep out-of-the-money puts (strikes like 2.5 and 10) indicate a hedge against a catastrophic failure or delisting scenario. The lack of meaningful in-the-money positioning suggests the market views the current price as a binary event waiting to happen, with neither side having a dominant conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2418096 |
| Address1 | 852 Winter Street |
| Address2 | Suite 250 |
| All Time High | 44.6 |
| All Time Low | 5.83 |
| Ask | 35.41 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,379,410 |
| Average Daily Volume3 Month | 724,893 |
| Average Volume | 724,893 |
| Average Volume10Days | 1,379,410 |
| Bid | 20.32 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 4.444 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.88 |
| Current Ratio | 11.938 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 28.69 |
| Day Low | 27.405 |
| Debt To Equity | 79.454 |
| Display Name | Zenas BioPharma |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,537,800 |
| Earnings Timestamp Start | 1,786,537,800 |
| Ebitda | -251,366,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.211 |
| Enterprise Value | 1,309,782,528 |
| Eps Current Year | -4.295 |
| Eps Forward | -2.265 |
| Eps Trailing Twelve Months | -9.1 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.756 |
| Fifty Day Average Change | 7.1239986 |
| Fifty Day Average Change Percent | 0.343226 |
| Fifty Two Week Change Percent | 124.18096 |
| Fifty Two Week High | 44.6 |
| Fifty Two Week High Change | -16.72 |
| Fifty Two Week High Change Percent | -0.37488788 |
| Fifty Two Week Low | 11.1 |
| Fifty Two Week Low Change | 16.779999 |
| Fifty Two Week Low Change Percent | 1.5117116 |
| Fifty Two Week Range | 11.1 - 44.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,234,200,000 |
| Float Shares | 41,061,948 |
| Forward Eps | -2.265 |
| Forward P E | -12.30905 |
| Free Cashflow | -166,289,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 167 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -193,587,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18293 |
| Held Percent Institutions | 0.90479 |
| Implied Shares Outstanding | 63,133,377 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-09-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts. |
| Long Name | Zenas BioPharma, Inc. |
| Market | us_market |
| Market Cap | 1,760,158,464 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1815193886 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -425,151,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,813,506,254 |
| Number Of Analyst Opinions | 8 |
| Open | 28.23 |
| Operating Cashflow | -210,478,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 271 2954 |
| Post Market Change | -0.099998474 |
| Post Market Change Percent | -0.3586746 |
| Post Market Price | 27.78 |
| Post Market Time | 1,783,985,468 |
| Previous Close | 28.74 |
| Price Eps Current Year | -6.4912686 |
| Price Hint | 2 |
| Price To Book | 6.2736273 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 11.744 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.860001 |
| Regular Market Change Percent | -2.99235 |
| Regular Market Day High | 28.69 |
| Regular Market Day Low | 27.405 |
| Regular Market Day Range | 27.405 - 28.69 |
| Regular Market Open | 28.23 |
| Regular Market Previous Close | 28.74 |
| Regular Market Price | 27.88 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 801,927 |
| Return On Assets | -0.29059 |
| Return On Equity | -1.3711301 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 63,133,377 |
| Shares Percent Shares Out | 0.19319999 |
| Shares Short | 12,196,436 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 10,879,470 |
| Short Name | Zenas BioPharma, Inc. |
| Short Percent Of Float | 0.288 |
| Short Ratio | 13.37 |
| Source Interval | 15 |
| State | MA |
| Symbol | ZBIO |
| Target High Price | 55.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 42.125 |
| Target Median Price | 44.5 |
| Total Cash | 717,204,992 |
| Total Cash Per Share | 11.36 |
| Total Debt | 266,828,992 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -9.1 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.1173 |
| Two Hundred Day Average Change | 2.7626991 |
| Two Hundred Day Average Change Percent | 0.109991886 |
| Type Disp | Equity |
| Volume | 801,927 |
| Website | https://zenasbio.com |
| Zip | 2,451 |